Abbott Laboratories (SNSE:ABT)
Chile · Delayed Price · Currency is CLP · Price in USD | Market Cap | 186.63T -8.7% |
| Revenue (ttm) | 46.92T +10.0% |
| Net Income | 4.55T -66.4% |
| EPS | 2,636.16 -66.2% |
| Shares Out | n/a |
| PE Ratio | 40.99 |
| Forward PE | 18.73 |
| Dividend | 2,335.06 (2.16%) |
| Ex-Dividend Date | Oct 15, 2026 |
| Volume | n/a |
| Open | n/a |
| Previous Close | 110.24 |
| Day's Range | n/a |
| 52-Week Range | 86.99 - 133.81 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 21, 2026 |
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, h... [Read more]
Financial Performance
In 2025, Abbott Laboratories's revenue was $44.33 billion, an increase of 5.67% compared to the previous year's $41.95 billion. Earnings were $6.50 billion, a decrease of -51.49%.
Financial numbers in USD Financial StatementsNews
Abbott’s Amulet 360 device shows efficacy in stroke incidence reduction
Abbott (ABT) announced one-year results for its investigational Amulet 360 Left Atrial Appendage, or LAA, Occluder from the VERITAS study, which show “meaningful” closure rates of the left atrial appe...
Late-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke
Late-breaking one-year VERITAS study results were presented at the Transcatheter Cardiovascular Therapeutics conference and simultaneously published in JACC: Cardiovascular Interventions; data show th...
Abbott announces Tectonic study met primary safety, effectiveness endpoints
Abbott (ABT) announced strong 30-day results from the Tectonic Coronary Artery Disease, CAD, Intravascular Lithotripsy, IVL, Investigational Device Exemption, IDE, Study evaluating the use of its inve...
Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System
SonicForce is an investigational coronary intravascular lithotripsy (IVL) system that uses acoustic pressure waves, similar to those used to break up kidney stones, to crack calcium in coronary arteri...
FDA posts adverse event report for Abbott’s Tendril SDX
The FDA posted Abbott’s (ABT) Tendril SDX in an adverse event report.
Abbott initiates pivotal trial for Cephea device
Abbott (ABT) announced it has initiated the CROWN-MV pivotal trial evaluating the safety and effectiveness of its investigational Cephea Mitral Valve System in treating people with symptomatic mitral ...
Abbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve disease
CROWN-MV trial will evaluate the safety and effectiveness of investigational Cephea mitral valve replacement device Abbott's Cephea is designed to provide a new, minimally invasive option for treating...
Abbott cut to Hold at Argus amid reimbursement uncertainty, competitive pressure
As previously reported, Argus downgraded Abbott (ABT) to Hold from Buy. Abbott is a well-run company with a long track record in its industry, but the near-term environment has seen…
Abbott downgraded to Hold from Buy at Argus
Argus downgraded Abbott (ABT) to Hold from Buy.
Abbott announces commercial availability of Oncodetect residual disease test
Abbott (ABT) announced the commercial availability of its next-generation Oncodetect MRD test, a personalized, tumor-informed, whole-genome sequencing test designed to provide molecular insights durin...
Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment
Powered by whole-genome sequencing and MAESTRO * technology, the next-generation Oncodetect test takes a distinct approach to MRD, tracking up to 5,000 patient-specific variants with a limit of detect...
Abbott presents data from Oncodetect MRD study
Abbott (ABT) announced new Beta-CORRECT data presented at the European Society for Medical Oncology, or ESMO, Congress showing that the whole-genome sequencing, or WGS,-based Oncodetect molecular resi...
Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer
Beta-CORRECT study shows a 10.6-fold higher risk of recurrence, reinforcing the prognostic value of molecular residual disease (MRD) testing 1 Building on its leadership in colorectal cancer screening...
Abbott price target lowered to $120 from $124 at Evercore ISI
Evercore ISI analyst Vijay Kumar lowered the firm’s price target on Abbott (ABT) to $120 from $124 and keeps an Outperform rating on the shares in conjunction with a preview…
Abbott price target raised to $120 from $119 at Wells Fargo
Wells Fargo raised the firm’s price target on Abbott (ABT) to $120 from $119 and keeps an Overweight rating on the shares. The firm is updating its Nutrition NewCo spin…
Abbott price target lowered to $125 from $130 at RBC Capital
RBC Capital lowered the firm’s price target on Abbott (ABT) to $125 from $130 and keeps an Outperform rating on the shares. The firm is taking a more cautious stance…
Abbott price target lowered to $118 from $135 at TD Cowen
TD Cowen lowered the firm’s price target on Abbott (ABT) to $118 from $135 and keeps a Buy rating on the shares. The firm said although they are disappointed by…
Abbott price target lowered to $125 from $134 at BTIG
BTIG analyst Marie Thibault lowered the firm’s price target on Abbott (ABT) to $125 from $134 and keeps a Buy rating on the shares. The firm is adjusting its model…
Abbott price target lowered to $118 from $120 at JPMorgan
JPMorgan lowered the firm’s price target on Abbott (ABT) to $118 from $120 and keeps an Overweight rating on the shares.
Abbott price target raised to $119 from $112 at Wells Fargo
Wells Fargo raised the firm’s price target on Abbott (ABT) to $119 from $112 and keeps an Overweight rating on the shares. The firm notes the company reported a mixed…
Abbott price target raised to $123 from $121 at Baird
Baird raised the firm’s price target on Abbott (ABT) to $123 from $121 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results where…
Abbott price target lowered to $122 from $125 at Citi
Citi analyst Joanne Wuensch lowered the firm’s price target on Abbott (ABT) to $122 from $125 and keeps a Buy rating on the shares. The company’s Q3 report missed expectations…
Abbott Laboratories Earnings Call Transcript: Q3 2026
Q3 sales rose 7% and adjusted EPS was $1.42, with growth accelerating. Plans call for a tax-free nutrition separation by end-2027; near-term outlook reflects EP and diabetes headwinds, while 2027 growth acceleration is expected.
Abbott Laboratories Earnings release: Q3 2026
Abbott Laboratories released its Q3 2026 earnings on October 21, 2026, summarizing the period's financial results.